Physician profile
Michael E Lim
NPI 1730294307
$29,373.79
in general payments reported to CMS, 2019-2025
36 companies · $4,585 in 2025
The $4,585 reported for 2025 was more than what 97% of Geriatric Medicine (Family Medicine) providers received nationally (typical 2025 total: $119).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,427 · 2020: $2,590 · 2021: $4,749 · 2022: $4,990 · 2023: $3,230 · 2024: $4,804 · 2025: $4,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,618.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,433.53 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Amgen INC. | $3,702.23 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $3,055.08 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $2,786.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Janssen Pharmaceuticals, INC | $2,575.18 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $2,384.10 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $1,500.09 | 2021-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Pfizer INC. | $1,162.17 | 2020-2025 | |
| Amarin Pharma, INC. | $862.47 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $790.35 | 2019-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $554.36 | 2021-2025 | |
| Esperion Therapeutics, INC. | $530.59 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $466.68 | 2020-2022 | |
| Corcept Therapeutics | $466.31 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $441.81 | 2023-2025 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $354.89 | 2019-2023 | |
| Glaxosmithkline, LLC. | $318.21 | 2023-2024 | Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $315.86 | 2024-2025 | Voquezna |
| Axsome Therapeutics, INC. | $271.46 | 2025 | Symbravo |
| Alexion Pharmaceuticals, INC. | $265.50 | 2023-2024 | Strensiq |
| Merck Sharp & Dohme LLC | $225.65 | 2019-2023 | Steglatro, Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.95 | 2024 | Xifaxan, Trulance |
| Exact Sciences Corporation | $172.19 | 2023-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $135.95 | 2024-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $81.00 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $55.15 | 2023-2024 | Inpefa |
| Currax Pharmaceuticals LLC | $50.18 | 2021 | |
| Edwards Lifesciences Corporation | $45.44 | 2025 | Sapien 3 Ultra Resilia |
| Abbvie INC. | $38.77 | 2021 | |
| Shield Therapeutics INC | $25.56 | 2025 | |
| Inspire Medical Systems, INC. | $20.00 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $18.13 | 2019 | |
| Ibsa Pharma INC. | $17.35 | 2024 | Tirosint, Licart, Flector |
| Alfasigma USA, INC. | $16.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.21 | 2021 | |
| Theracosbio, LLC | $12.40 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.